McKesson Corporation (MCK : NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends

McKesson Corporation (MCK : NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends


Report Summary

McKesson Corporation (MCK : NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of McKesson Corporation's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about McKesson Corporation including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses McKesson Corporation's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of McKesson Corporation's overall strategic standing and supports informed decision-making and strategic planning.

The report also covers McKesson Corporation's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares McKesson Corporation's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by McKesson Corporation enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

McKesson Corporation, founded in 1833, is one of the oldest healthcare industry. It operates as a diversified healthcare services and information technology company that plays a vital role in improving healthcare outcomes around the world. McKesson provides pharmaceutical distribution, medical supplies, healthcare management software, and biopharmaceutical services, making it a pivotal player in healthcare logistics and technology solutions.

With a rich history spanning over 190 years, McKesson continues to be a cornerstone in global healthcare, addressing the needs of patients, healthcare providers, and pharmaceutical companies through its robust distribution networks and technology platforms.

McKesson Corporation in the News:-
  • 09-Oct-2024 - InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
  • 01-Oct-2024 - McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies
  • 25-Sep-2024 - VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
  • 10-Sep-2024 - ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
  • 09-Sep-2024 - RYTELOTM (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
Scope
  • Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
  • Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
  • Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
  • Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
  • Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
  • Comprehensive Understanding of the McKesson Corporation's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
  • Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
  • Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
  • Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
  • Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
  • Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company McKesson Corporation:
  • McKesson Corporation Value Chain Analysis
  • McKesson Corporation Porter's Five Forces Analysis
  • McKesson Corporation VRIO Analysis
  • McKesson Corporation BCG Analysis
  • McKesson Corporation Segmentation, Targeting and Positioning (STP) Analysis
  • McKesson Corporation Ansoff Matrix Analysis


COMPANY EXECUTIVE SUMMARY
Tables
Charts
McKesson Corporation - Key Company Facts
McKesson Corporation - Company Description
McKesson Corporation - Top Executives
McKesson Corporation- Top Executives Biographies
McKesson Corporation- Head Office & Locations
Head Office - Country
Key Subsidiaries
Key Joint Ventures
McKesson Corporation - Products and Services
Products
Services
McKesson Corporation - Historic Events
McKesson Corporation – Company’s Management Discussion
McKesson Corporation – Company’s Mission and Vision
Mission
Vision
McKesson Corporation - Corporate Strategy
McKesson Corporation - Business Description
U.S. Pharmaceutical Segment
Prescription Technology Solutions (RxTS) Segment
Medical-Surgical Solutions Segment
International Segment
McKesson Corporation - ESG Spotlight
Environment
Social
Corporate Governance
McKesson Corporation - SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
McKesson Corporation – PESTLE Analysis
Overview
Political Factors
Economic Factors
Social Factors
Technological Factors
Legal Factors
Environmental Factors
McKesson Corporation - Financial Deep Dive
Share Price Trend - Oct-2023 to Oct-2024 (Average Share Closing Price)
Profit and Loss Statement
Summary of Profit and Loss Statement
Balance Sheet
Summary of Balance Sheet
Cash Flow Statement
Summary of Cash Flow Statement
Key Financial Ratio Analysis
McKesson Corporation - Ratio Charts
Activity Ratio Charts
Growth Ratios Charts
Leverage Ratio Charts
Liquidity Ratio Charts
Profitability Ratio Charts
Competing Players
Snapshot of Competing Players
Cencora Inc
Key Company Facts
Company Description
Snapshot of Competing Players
Cardinal Health Inc
Key Company Facts
Company Description
Snapshot of Competing Players
Johnson & Johnson Services, Inc.
Key Company Facts
Company Description
Snapshot of Competing Players
Medtronic plc
Key Company Facts
Company Description
Snapshot of Competing Players
Stryker Corporation
Key Company Facts
Company Description
McKesson Corporation - In the News
09-Oct-2024- InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
01-Oct-2024- McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies
25-Sep-2024- VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
10-Sep-2024- ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
09-Sep-2024- RYTELOTM (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
05-Sep-2024- McKesson Corporation Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity Partners
03-Sep-2024- The US Oncology Network Extends its Reach in Illinois as Illinois CancerCare Joins The Network
02-Jul-2024- McKesson Releases Fiscal Year 2024 Impact Report
26-Jun-2024- McKesson Corporation Announces First Quarter Fiscal 2025 Earnings Release Date
26-Jun-2024- McKesson ideaShare Ignites and Inspires Independent Community Pharmacies
19-Jun-2024- CAMCEVI (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson
03-Jun-2024- McKesson's Board of Directors Elects Deborah Dunsire as New Director
03-Jun-2024- Real-World Research Presented at ASCO 2024 Indicates Clinical Trial Participation by Older Adults with Cancer Does Not Affect Emergency Room Visits or Hospice Enrollment
20-Dec-2023- FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
16-Aug-2023- Genpact Extends Relationship to Transform McKesson’s Finance Operations for Enhanced Service and Competitive Growth
10-Jul-2023- Cancer center of kansas joins the us oncology network
22-Jun-2023- Mckesson unveils new private brand of over-the-counter pharmacy products
05-Jun-2023- Research presented at asco 2023 shows implementing value-based care strategies such as dose rounding reduces drug waste and total cost of care
05-Apr-2023- Biologics by mckesson named the exclusive pharmacy for fda- approved skyclarys (omaveloxolone) for the treatment of friedreich's ataxia
17-Jan-2023- The us oncology network continues its rapid growth into new communities, adding epic care and nexus health
22-Dec-2022- Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound), fda approved for treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor
McKesson Corporation- Key Deals
17-Oct-2024 - Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology
26-Aug-2024 - McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute’s Core Ventures
19-Sep-2022 - Mckesson signs agreement to acquire rx savings solutions
09-May-2022 - Oncohealth secures strategic investments from arsenal capital partners & mckesson corporation
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Financial Deep Dive
Financial Ratios -
Activity Ratios
Growth Ratios
Leverage Ratios
Liquidity Ratios
Market Ratios
Profitability Ratios
Research Methodology
Disclaimer
Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings